American Gene Technologies
PrivateLast Round
Convertible Debt
Oct 31, 2023
Est. Valuation
$15.21M
Total Funding Raised
$73.73M
Company Overview
American Gene Technologies operates in Healthcare & Life Sciences and is based in Rockville, Maryland. Its latest recorded funding round was a Convertible Debt round in October 2023.
American Gene Technologies is a biotechnology company that develops gene and cell therapies aimed at curing infectious diseases, cancers, and inherited disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
American Gene Technologies Comparables
Compare American Gene Technologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Addimmune | 91% | |
| Excision BioTherapeutics | 82% | |
| PROVIREX Genome Editing Therapies GmbH | 77% |
For institutional investors. Book with your work email.
American Gene Technologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Oct 31, 2023 | ||||
| Series F | Sep 22, 2023 | ||||
| M&A | Aug 9, 2023 | ||||
| Series F | Apr 22, 2022 | ||||
| VC Round | Apr 15, 2021 | ||||
Series D1 | Nov 30, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
American Gene Technologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HealthTech Fund (An Alumni Ventures Fund) | Series D1 |
| ROC Venture Group | Series F |
| Ride Wave Ventures | Series F |
| NIH RADx | Grant |
| Gaingels | Series F, VC Round |
| 10X Capital Venture Acquisition Corp. III | M&A |
| Alumni Ventures | Series F |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 22, 2025
Presented at the International AIDS Society 2025 conference.
- Jul 22, 2025
Promising results from AGT103-T HIV functional cure program presented at IAS 2025.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 2, 2026
American Gene presents at the NIBA 153rd Investment Conference in Florida on Oct 6th-7th '26 and is available for one-on-one investor meetings on Oct 7th '26.
- attends_eventAug 25, 2026
American Gene participates in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York from Sep 9th to Sep 10th '26, with Drew Palin MD delivering an investor presentation and meeting investors.
For institutional investors. Book with your work email.
American Gene Technologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about American Gene Technologies's valuation, stock price, and market status.
Is American Gene Technologies a public or private company?
American Gene Technologies is a private company.
What is the current stock price of American Gene Technologies?
American Gene Technologies is a private company, so its shares have no public market price. Caplight tracks American Gene Technologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is American Gene Technologies worth (valuation)?
American Gene Technologies's valuation is estimated at $15.2M based on funding round data.
Can I buy American Gene Technologies stock?
American Gene Technologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was American Gene Technologies's last funding round?
American Gene Technologies's most recent funding round was Convertible Debt on October 31, 2023.
Who are the main investors in American Gene Technologies?
Key investors in American Gene Technologies include Ride Wave Ventures, 10X Capital Venture Acquisition Corp. III.
Will American Gene Technologies IPO soon?
No public IPO plans have been announced for American Gene Technologies.
How can I track American Gene Technologies secondary market activity?
Caplight tracks bids, offers, and trades in American Gene Technologies's shares on secondary markets.